… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … 10 (LCA10). Presentation title : Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ Proof-of-concept …
… A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology Key Updates Dr. Peter A. Beal joins … of RNA-based therapeutics, particularly in the area of RNAediting. As an expert in the field of ADAR and A-to-I …
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … advisory board. "Dr. Yu is a pioneer of targeted RNAediting to correct protein translation defects caused by …
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla